Tscan Therapeutics Stock Analysis
| TCRX Stock | USD 4.77 0.13 2.80% |
Tscan Therapeutics is overvalued with Real Value of 4.08 and Target Price of 10.75. The main objective of Tscan Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Tscan Therapeutics is worth, separate from its market price. There are two main types of Tscan Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Tscan Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Tscan Therapeutics is usually not traded on Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day. Tscan Stock trading window is adjusted to America/New York timezone.
Tscan |
Tscan Stock Analysis Notes
About 86.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.11. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Tscan Therapeutics recorded a loss per share of 0.95. The entity last dividend was issued on the 13th of September 1970. TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts. Tscan Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 115 people. To find out more about Tscan Therapeutics contact the company at 857 399 9500 or learn more at https://www.tscan.com.Tscan Therapeutics Investment Alerts
| Tscan Therapeutics generated a negative expected return over the last 90 days | |
| Tscan Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 21.05 M. Net Loss for the year was (89.22 M) with loss before overhead, payroll, taxes, and interest of (46.28 M). | |
| Tscan Therapeutics currently holds about 125.6 M in cash with (61.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 86.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: TScan Therapeutics, Inc. Shares Bought by Brown Brothers Harriman Co. |
Tscan Therapeutics Upcoming and Recent Events
Earnings reports are used by Tscan Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
| 13th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 13th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Tscan Largest EPS Surprises
Earnings surprises can significantly impact Tscan Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-12 | 2024-09-30 | -0.2918 | -0.25 | 0.0418 | 14 | ||
2024-05-13 | 2024-03-31 | -0.26 | -0.32 | -0.06 | 23 | ||
2024-03-06 | 2023-12-31 | -0.29 | -0.21 | 0.08 | 27 |
Tscan Therapeutics Environmental, Social, and Governance (ESG) Scores
Tscan Therapeutics' ESG score is a quantitative measure that evaluates Tscan Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Tscan Therapeutics' operations that may have significant financial implications and affect Tscan Therapeutics' stock price as well as guide investors towards more socially responsible investments.
Tscan Therapeutics Thematic Classifications
In addition to having Tscan Therapeutics stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
 | BiotechBiotechnology and pharmaceuticals production and services |
Tscan Stock Institutional Investors
| Shares | Stempoint Capital Lp | 2024-09-30 | 861 K | Checkpoint Capital Lp | 2024-09-30 | 825.3 K | Lmr Partners Llp | 665.5 K | Dc Funds, Lp | 2024-09-30 | 630 K | State Street Corp | 2024-06-30 | 608.1 K | Amvescap Plc. | 2024-06-30 | 499.9 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 483.3 K | Abrdn Plc | 2024-09-30 | 371.7 K | Northern Trust Corp | 2024-09-30 | 324.3 K | Ecor1 Capital, Llc | 2024-09-30 | 5 M | Blackrock Inc | 2024-06-30 | 4.5 M |
Tscan Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 254.58 M.Tscan Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.33) | (0.34) | |
| Return On Capital Employed | (0.39) | (0.40) | |
| Return On Assets | (0.33) | (0.34) | |
| Return On Equity | (0.59) | (0.56) |
Management Efficiency
Tscan Therapeutics has return on total asset (ROA) of (0.2336) % which means that it has lost $0.2336 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5592) %, meaning that it created substantial loss on money invested by shareholders. Tscan Therapeutics' management efficiency ratios could be used to measure how well Tscan Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.34 in 2024. Return On Capital Employed is likely to drop to -0.4 in 2024. At this time, Tscan Therapeutics' Net Tangible Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 3.8 M in 2024, whereas Total Assets are likely to drop slightly above 166.9 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.30 | 1.72 | |
| Tangible Book Value Per Share | 2.30 | 1.72 | |
| Enterprise Value Over EBITDA | (4.26) | (4.48) | |
| Price Book Value Ratio | 2.53 | 2.66 | |
| Enterprise Value Multiple | (4.26) | (4.48) | |
| Price Fair Value | 2.53 | 2.66 | |
| Enterprise Value | 341.5 M | 358.6 M |
The strategic initiatives led by Tscan Therapeutics' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Operating Margin (31.10) | Beta 0.782 | Return On Assets (0.23) | Return On Equity (0.56) |
Technical Drivers
As of the 29th of November, Tscan Therapeutics has the Coefficient Of Variation of (2,324), risk adjusted performance of (0.03), and Variance of 13.44. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Tscan Therapeutics, as well as the relationship between them.Tscan Therapeutics Price Movement Analysis
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Tscan Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Tscan Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Tscan Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tscan Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tscan Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Tscan Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Tscan Therapeutics Outstanding Bonds
Tscan Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Tscan Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Tscan bonds can be classified according to their maturity, which is the date when Tscan Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Tscan Therapeutics Predictive Daily Indicators
Tscan Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Tscan Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Tscan Therapeutics Corporate Filings
8K | 21st of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 19th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 8th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
8K | 1st of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 21st of October 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
F4 | 24th of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 27th of August 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Tscan Therapeutics Forecast Models
Tscan Therapeutics' time-series forecasting models are one of many Tscan Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Tscan Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Tscan Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Tscan Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Tscan shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Tscan Therapeutics. By using and applying Tscan Stock analysis, traders can create a robust methodology for identifying Tscan entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (4.24) | (4.45) | |
| Operating Profit Margin | (4.44) | (4.66) | |
| Net Loss | (4.24) | (4.45) | |
| Gross Profit Margin | (3.19) | (3.35) |
Current Tscan Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Tscan analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Tscan analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 10.75 | Strong Buy | 8 | Odds |
Most Tscan analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Tscan stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Tscan Therapeutics, talking to its executives and customers, or listening to Tscan conference calls.
Tscan Stock Analysis Indicators
Tscan Therapeutics stock analysis indicators help investors evaluate how Tscan Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Tscan Therapeutics shares will generate the highest return on investment. By understating and applying Tscan Therapeutics stock analysis, traders can identify Tscan Therapeutics position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 125.1 M | |
| Long Term Debt | 26.7 M | |
| Common Stock Shares Outstanding | 65.6 M | |
| Total Stockholder Equity | 150.9 M | |
| Property Plant And Equipment Net | 71.2 M | |
| Cash And Short Term Investments | 192 M | |
| Cash | 133.4 M | |
| Accounts Payable | 2.4 M | |
| Net Debt | -40.9 M | |
| 50 Day M A | 5.0894 | |
| Total Current Liabilities | 29.8 M | |
| Other Operating Expenses | 114.5 M | |
| Non Current Assets Total | 77.9 M | |
| Non Currrent Assets Other | 6.7 M | |
| Stock Based Compensation | 5.2 M |
Additional Tools for Tscan Stock Analysis
When running Tscan Therapeutics' price analysis, check to measure Tscan Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tscan Therapeutics is operating at the current time. Most of Tscan Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tscan Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tscan Therapeutics' price. Additionally, you may evaluate how the addition of Tscan Therapeutics to your portfolios can decrease your overall portfolio volatility.